Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10

Rhea-AI Summary

Eiger BioPharmaceuticals (Nasdaq:EIGR) is set to host a conference call on March 10, 2022, at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results. The call aims to provide a comprehensive business update for investors. Eiger is focused on developing innovative therapies targeting Hepatitis Delta Virus (HDV) and other rare diseases. Notably, all five of its rare disease programs have received FDA Breakthrough Therapy Designation, signifying strong progress in its clinical pipeline.

Positive

• All five rare disease programs have FDA Breakthrough Therapy Designation.
• Two first-in-class therapies in Phase 3 targeting viral replication.

Negative

• None.

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 10, 2022 at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a business update.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com.  To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 4338659.  The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases.  The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.  All five Eiger rare disease programs have been granted FDA Breakthrough Therapy Designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors:
Sri Ryali – CFO
sryali@eigerbio.com

Sylvia Wheeler – Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Media:
Aljanae Reynolds – Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-fourth-quarter--full-year-2021-financial-results-and-business-update-on-thursday-march-10-301490121.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What are the upcoming conference call details for Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals will host a conference call on March 10, 2022, at 4:30 PM ET to discuss its financial results.

What is the focus of Eiger BioPharmaceuticals in their clinical programs?

Eiger focuses on developing therapies for Hepatitis Delta Virus and other serious rare diseases.

What recent designations have Eiger's programs received?

All five of Eiger's rare disease programs have been granted FDA Breakthrough Therapy Designation.

Where can I access the conference call for Eiger BioPharmaceuticals?

The live and replayed webcast of the call will be available at www.eigerbio.com.